NEW HAVEN, Conn., March 15, 2021 /PRNewswire/ -- Biohaven
Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a
commercial-stage biopharmaceutical company with a marketed drug for
the acute treatment of migraine and a portfolio of innovative,
late–stage product candidates targeting neurological diseases,
including rare disorders, today announced that it has commenced an
underwritten public offering of $200
million of its common shares. All of the common shares
to be sold in the offering will be offered by Biohaven. In
addition, Biohaven expects to grant the underwriter a 30-day option
to purchase up to an additional $30
million of common shares at the public offering price, less
underwriting discounts and commissions. The offering is
subject to market and other conditions, and there can be no
assurance as to whether or when the offering may be completed, or
the actual size or terms of the offering.
Goldman Sachs & Co. LLC is acting as the book-running
manager of the offering.
The offering is being made only by means of a prospectus
supplement and the accompanying prospectus, copies of which, when
available, may be obtained from the offices of Goldman Sachs &
Co. LLC, Attention: Prospectus Department, 200 West Street,
New York, NY 10282, telephone:
1–866-471-2526, facsimile: 212-902-9316 or by emailing
Prospectus-ny@ny.email.gs.com.
The shares will be issued pursuant to an effective shelf
registration statement on Form S-3. Before investing in the
offering, interested parties should read the prospectus and related
prospectus supplement for this offering, the documents incorporated
by reference therein and the other documents Biohaven has filed
with the Securities and Exchange Commission. This press
release shall not constitute an offer to sell or a solicitation of
an offer to buy any of these securities, nor shall there be any
sale of these securities in any state or jurisdiction in which such
an offer, solicitation or sale would be unlawful prior to
registration or qualification under the applicable securities laws
of such state or jurisdiction.
Contact
Dr. Vlad Coric
Chief Executive Officer
Biohaven Pharmaceutical Holding Company Ltd.
Phone: (203) 404-0410
Email: vlad.coric@biohavenpharma.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biohaven-announces-proposed-public-offering-of-common-shares-301247671.html
SOURCE Biohaven Pharmaceutical Holding Company Ltd.